Clinical Trial Search

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Change From Baseline in CRT as Measured by SD-OCT on Day 29 — 44.0 μm

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA

Primary: Best Corrected Visual Acuity (BCVA) — 7.0 letters

Primary: The Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss at 12 Months. — 22; 14 percentage of participants

Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters

Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Change From Baseline Visual Acuity at 6 Months — 3.8 number of letters

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs) — 0; 0; 0; 0 Participants

Primary: Change in Mean Central Subfield Thickness (CST) — -36.6; 1.7 microns — p=0.04

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…

Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 — 1.17; 1.05; 0.87 score on a scale — p=0.919

Primary: Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — 0.024; 0.050; 0.363; 0.285 mm — p=0.236

Primary: Best Corrected Visual Acuity (BCVA) — 2.0 letters

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients

Primary: Number of Subjects With Positive LUCENTIS® Retreatment Status at Day 84 — 25; 25 Participants

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…

Primary: Vitreal VEGF Levels. — 735.48; 626.09; 141.11; 235.81 pg/ml